BioTime, Inc. (BTX)

1.26
0.06 5.00
AMEX
Prev Close 1.20
Open 1.21
Day Low/High 1.21 / 1.27
52 Wk Low/High 0.66 / 2.90
Volume 500.90K
Exchange AMEX
Shares Outstanding 149.36B
Market Cap 186.70M
Div & Yield N.A. (N.A)
BioTime To Present At The Raymond James 39th Annual Institutional Investor Conference

BioTime To Present At The Raymond James 39th Annual Institutional Investor Conference

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer of...

BioTime Announces Appointment Of Gary S. Hogge, DVM, MS, PhD, As Sr. Vice President, Clinical And Medical Affairs

BioTime Announces Appointment Of Gary S. Hogge, DVM, MS, PhD, As Sr. Vice President, Clinical And Medical Affairs

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced the appointment of Gary S.

BioTime Appoints Cavan Redmond To Its Board Of Directors

BioTime Appoints Cavan Redmond To Its Board Of Directors

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, announced the appointment of Cavan Redmond as an independent...

Data From BioTime's OpRegen® And Vision Restoration Programs To Be Presented At ARVO 2018

Data From BioTime's OpRegen® And Vision Restoration Programs To Be Presented At ARVO 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that two abstracts have been accepted and will be...

BioTime To Participate At The BIO CEO And Investor Conference In New York, February 12th And 13th 2018

BioTime To Participate At The BIO CEO And Investor Conference In New York, February 12th And 13th 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer of...

Commit To Buy BioTime At $2, Earn 12% Annualized Using Options

Commit To Buy BioTime At $2, Earn 12% Annualized Using Options

Investors considering a purchase of BioTime Inc shares, but cautious about paying the going market price of $2.82/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2 strike, which has a bid at the time of this writing of 15 cents.

Renevia® Data From The Successful Pivotal Trial To Be Presented At The IMCAS Conference

Renevia® Data From The Successful Pivotal Trial To Be Presented At The IMCAS Conference

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the successful pivotal...

BioTime To Present At The Noble Capital Markets 14th Annual Institutional Investor Conference In Fort Lauderdale, January 29, 2018

BioTime To Present At The Noble Capital Markets 14th Annual Institutional Investor Conference In Fort Lauderdale, January 29, 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will...

BioTime Announces Clinical And Corporate Milestone Targets For 2018

BioTime Announces Clinical And Corporate Milestone Targets For 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced its 2018 clinical and corporate milestone targets.

BioTime Announces Issuance Of 41 New Patents To Expand And Bolster Its Patent Estate

BioTime Announces Issuance Of 41 New Patents To Expand And Bolster Its Patent Estate

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced the issuance of 41 new patents over the past 12...

AgeX Therapeutics To Present At Biotech Showcase Annual Conference

AgeX Therapeutics To Present At Biotech Showcase Annual Conference

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc.

AgeX Therapeutics Identifies Genes Implicated In Tissue Regeneration And Cancer

AgeX Therapeutics Identifies Genes Implicated In Tissue Regeneration And Cancer

AgeX Therapeutics, Inc. ( AgeX), a subsidiary of BioTime, Inc.

BioTime To Participate In The LifeSci Advisors Corporate Access Event In San Francisco, January 8 - 10, 2018

BioTime To Participate In The LifeSci Advisors Corporate Access Event In San Francisco, January 8 - 10, 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer, and...

Additional Renevia Data From The Successful Pivotal Trial Was Presented At The IFATS Conference

Additional Renevia Data From The Successful Pivotal Trial Was Presented At The IFATS Conference

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the successful pivotal...

Data From BioTime's Renevia® Program To Be Presented At IFATS Conference

Data From BioTime's Renevia® Program To Be Presented At IFATS Conference

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that detailed data from the successful pivotal...

BioTime Presents Updated OpRegen® Phase I/IIa Trial Data At AAO

BioTime Presents Updated OpRegen® Phase I/IIa Trial Data At AAO

BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that an abstract related to one of its...

BioTime To Participate In Upcoming Conferences

BioTime To Participate In Upcoming Conferences

BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that its management will participate in...

BioTime Reports Third Quarter Results And Recent Corporate Accomplishments

BioTime Reports Third Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company developing and commercializing products addressing degenerative diseases, today reported financial results for the third quarter...

BioTime To Participate In The Jefferies 2017 London Healthcare Conference

BioTime To Participate In The Jefferies 2017 London Healthcare Conference

BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive...

BioTime To Announce Third Quarter 2017 Results On November 9, 2017

BioTime To Announce Third Quarter 2017 Results On November 9, 2017

BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that it will release third quarter...

BioTime, Inc. Announces Closing Of Public Offering And Underwriters' Full Exercise Of Over-Allotment Option

BioTime, Inc. Announces Closing Of Public Offering And Underwriters' Full Exercise Of Over-Allotment Option

BioTime, Inc. ("BioTime") (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced the closing of its...

BioTime, Inc. Announces Pricing Of $25.0 Million Public Offering Of Common Stock

BioTime, Inc. Announces Pricing Of $25.0 Million Public Offering Of Common Stock

BioTime, Inc. ("BioTime") (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced the pricing of an...

BioTime, Inc. Announces Proposed Public Offering Of Common Stock

BioTime, Inc. Announces Proposed Public Offering Of Common Stock

BioTime, Inc. ("BioTime") (NYSE American and TASE: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced its intent to offer...

BioTime Announces First Patient In U.S. Clinical Trial Treated For Facial Volume Deficit

BioTime Announces First Patient In U.S. Clinical Trial Treated For Facial Volume Deficit

BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today reported that an investigator-led clinical trial has...

BioTime And Processa Announce Their Intention To Enter Into A HyStem® Sublicense For Drug Delivery

BioTime And Processa Announce Their Intention To Enter Into A HyStem® Sublicense For Drug Delivery

BioTime, Inc. (NYSE American: BTX), a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases, today reached agreement on terms to sublicense certain...

BioTime To Present At The Cell And Gene Meeting On The Mesa

BioTime To Present At The Cell And Gene Meeting On The Mesa

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Jim Knight, SVP, Head of Corporate...

TheStreet Quant Rating: D (Sell)